CRESCI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.259
EU - Europa 1.170
AS - Asia 320
AF - Africa 4
OC - Oceania 1
Totale 3.754
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.253
RU - Federazione Russa 516
PL - Polonia 216
IE - Irlanda 143
SE - Svezia 116
SG - Singapore 97
HK - Hong Kong 85
CN - Cina 70
IT - Italia 64
DE - Germania 30
FI - Finlandia 27
JO - Giordania 26
IN - India 22
UA - Ucraina 22
GB - Regno Unito 12
FR - Francia 8
CH - Svizzera 7
VN - Vietnam 7
CA - Canada 6
TR - Turchia 6
BE - Belgio 4
CI - Costa d'Avorio 4
ES - Italia 3
MY - Malesia 2
NL - Olanda 2
IL - Israele 1
KR - Corea 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 3.754
Salva come PNG Salva come JPEG
Città #
Santa Clara 608
Fairfield 262
Warsaw 216
Chandler 168
Dublin 143
Ashburn 114
Cambridge 107
Seattle 106
Woodbridge 100
Wilmington 96
Houston 90
Singapore 85
Hong Kong 50
Ann Arbor 43
Jacksonville 39
Princeton 36
Buffalo 33
Lawrence 32
Altamura 31
Boston 24
Kent 24
Beijing 21
Florence 18
Mumbai 18
Shanghai 18
Medford 16
Boardman 15
Moscow 15
San Diego 12
New York 10
Los Angeles 9
Bern 7
Falls Church 7
Andover 6
Dong Ket 6
Falkenstein 5
Helsinki 5
Izmir 5
Abidjan 4
Brussels 4
West Jordan 4
Frankfurt Am Main 3
Glen Burnie 3
Milan 3
Ottawa 3
Selvazzano Dentro 3
Toronto 3
Auburn Hills 2
Barcelona 2
Chennai 2
Hillsboro 2
Norwalk 2
Phoenix 2
Rome 2
Shah Alam 2
Tappahannock 2
Amsterdam 1
Auckland 1
Bremen 1
Esslingen am Neckar 1
Forest City 1
Haifa 1
Islington 1
Kilburn 1
Laurel 1
Leawood 1
London 1
Louisville 1
Madrid 1
Naaldwijk 1
New Bedfont 1
Northridge 1
Redmond 1
Seoul 1
Sindelfingen 1
Stockholm 1
Taipei 1
Tashkent 1
Tianjin 1
Washington 1
Wuhan 1
Yangon 1
Zibo 1
Totale 2.675
Salva come PNG Salva come JPEG
Nome #
Fit and motivated: outcome predictors in patients starting a program for lifestyle change. 249
False and true pre-treatment predictors of weight loss in obese patients starting a program for lifestyle change. 184
Platelet-activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line (HEC-1A) 161
Lower and higher-potency statins on glycemic control in type 2 diabetes: A retrospective cohort study 153
Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. 141
Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment 121
Reply to Josef Finsterer “MELAS requires broad clinical and genetic work-up” 119
Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity. 118
Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months 117
Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study 116
Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. 115
Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. 111
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. 110
Insulin resistance and obesity affect monocyte-derived dendritic cell phenotype and function 109
Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study 108
Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. 107
EFFECTS OF INSULIN AND GLUCOSE ON THE GROWTH AND THE RELEASE OF EXTRACELLULAR-MATRIX COMPONENTS BY BOVINE BONE ENDOTHELIAL-CELLS 102
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. 102
All roads bring to Rome: a different way for predicting success in the therapy of obesity through psychological features 99
Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials 99
Obesity as a risk factor for hospitalization in COronaVirus Disease-19 (COVID-19) patients: Analysis of the Tuscany regional database 96
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials 94
Hyperparathyroidim: Is It Really the Major Factor Affecting Glucose Tolerance in Uremia. 90
Doses of insulin and its analogues and cancer occurence in insulin-treated type 2 diabetic patients. 88
National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. 87
Motivational readiness to change in lifestyle modification programs 84
Efficacy and effects of bariatric surgery in the treatment of obesity: Network meta-analysis of randomized controlled trials 79
Body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) e waist body mass index (wBMI): Which is better? 76
Online group lifestyle modification programs for obesity during the COVID-19 pandemic: The EDucation ONline (EDON) retrospective study 76
Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS) 76
Inflammation markers and metabolic characteristic of subjects with one-hour plasma glucose levels 75
MANAGEMENT OF HYPERGLICEMIA IN TYPE 2 DIABETES: A CONSENSUS ALGORITHM FOR THE INITIATION AND ADJUSTMENT OF THERAPY: A CONSENSUS STATEMENT FROM THE AMERICAN DIABETES ASSOCIATION AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 72
Effectiveness of Low Carbohydrate diets for long-term weight loss in obese individuals: a meta-analysis of randomized controlled trials 68
Effectiveness of intermittent fasting for weight loss in individuals with obesity: A meta-analysis of randomized controlled trials 59
Obesity therapy: How and why? 58
Factor analysis as a tool to explore the heterogeneity of type 2 diabetes: A feasibility study 52
Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials 5
Totale 3.776
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020327 0 0 0 0 0 69 60 64 56 36 33 9
2020/2021287 23 31 42 21 14 20 6 23 28 34 26 19
2021/2022238 5 15 19 7 14 11 5 12 13 16 49 72
2022/2023654 60 122 28 56 40 118 79 20 101 3 15 12
2023/2024265 12 33 40 8 12 33 16 56 3 16 28 8
2024/20251.400 66 192 129 284 493 236 0 0 0 0 0 0
Totale 3.776